Stock Events

Stock Events

Alpine Immune Sciences 

$64.97
31
+$0.01+0.02% Friday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

9MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.42
-0.23
-0.04
0.15
Expected EPS
-0.41
Actual EPS
-0.28

Financials

-54.66%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
58.88MRevenue
-32.18MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALPN. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Xencor
XNCR
Mkt Cap990.34M
Xencor competes in the development of engineered monoclonal antibodies for the treatment of autoimmune diseases, cancer, and allergic diseases, similar to Alpine's focus on immune modulation therapies.
Novartis
NVS
Mkt Cap279.67B
Novartis offers a broad range of immunology and oncology therapies, directly competing with Alpine's research and development in similar therapeutic areas.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb has a strong portfolio in oncology and immunology, including immune checkpoint inhibitors, competing with Alpine's immune modulation approaches.
Merck
MRK
Mkt Cap277.02B
Merck is known for its cancer immunotherapy drug Keytruda, which competes with Alpine's development of novel immunotherapies.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, with its acquisition of Kite Pharma, has become a leader in cell therapy for cancer, competing with Alpine's cancer immunotherapy research.
AMGEN
AMGN
Mkt Cap178B
Amgen has a diverse biotechnology portfolio, including treatments for cancer and inflammatory diseases, competing with Alpine's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals is involved in the development of monoclonal antibodies for cancer and other diseases, competing with Alpine's antibody-based therapies.
Incyte
INCY
Mkt Cap19.36B
Incyte Corporation focuses on the discovery of novel therapeutics for cancer and other serious diseases, competing with Alpine's therapeutic development.

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Show more...
CEO
Mitchell Gold
Employees
142
Country
United States
ISIN
US02083G1004
WKN
000A2DU89

Listings

0 Comments

Share your thoughts

FAQ

What is Alpine Immune Sciences stock price today?▼
The current price of ALPN is $64.97 USD — it has increased by +0.02% in the past 24 hours. Watch Alpine Immune Sciences stock price performance more closely on the chart.
What is Alpine Immune Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Alpine Immune Sciences stocks are traded under the ticker ALPN.
What were Alpine Immune Sciences earnings last quarter?▼
ALPN earnings for the last quarter are -0.28 USD per share, whereas the estimation was -0.41 USD resulting in a +31.71% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Alpine Immune Sciences revenue for the last year?▼
Alpine Immune Sciences revenue for the last year amounts to 58.88M USD.
What is Alpine Immune Sciences net income for the last year?▼
ALPN net income for the last year is -32.18M USD.
How many employees does Alpine Immune Sciences have?▼
As of May 06, 2026, the company has 142 employees.
In which sector is Alpine Immune Sciences located?▼
Alpine Immune Sciences operates in the Technology sector.
When did Alpine Immune Sciences complete a stock split?▼
The last stock split for Alpine Immune Sciences was on July 25, 2017 with a ratio of 1:4.
Where is Alpine Immune Sciences headquartered?▼
Alpine Immune Sciences is headquartered in Seattle, United States.